^
    Back
    Association details:
    Biomarker:ER D538G
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:camizestrant (AZD9833) (Selective estrogen receptor degrader)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    4379 / 22 - Not all selective estrogen receptor degraders are equal - Preclinical comparison of AZD9833, AZD9496 and fulvestrant

    Published date:
    05/15/2020
    Excerpt:
    However, in the patient derived xenograft CTC174 harbouring an ESR1 D538G mutation, AZD9833 caused equivalent anti-tumour and ERα degradation effects to supraclinical fulvestrant.